Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1

ABSTRACT: A SARS-CoV-2 RBD219-N1C1 (RBD219-N1C1) recombinant protein antigen formulated on Alhydrogel® has recently been shown to elicit a robust neutralizing antibody response against SARS-CoV-2 pseudovirus in mice. The antigen has been produced under current good manufacturing practices (cGMPs) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jungsoon, Liu, Zhuyun, Chen, Wen-Hsiang, Wei, Junfei, Kundu, Rakhi, Adhikari, Rakesh, Rivera, Joanne Altieri, Gillespie, Portia M., Strych, Ulrich, Zhan, Bin, Hotez, Peter J., Bottazzi, Maria Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Biotechnological Products and Process Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102132/
https://www.ncbi.nlm.nih.gov/pubmed/33959781
http://dx.doi.org/10.1007/s00253-021-11281-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102132/
https://www.ncbi.nlm.nih.gov/pubmed/33959781
http://dx.doi.org/10.1007/s00253-021-11281-3

Ejemplares similares